Immune-Modified Response Evaluation Criteria In Solid Tumors (imRECIST): Refining Guidelines to Assess the Clinical Benefit of Cancer Immunotherapy

Purpose Treating solid tumors with cancer immunotherapy (CIT) can result in unconventional responses and overall survival (OS) benefits that are not adequately captured by Response Evaluation Criteria In Solid Tumors (RECIST) v1.1. We describe immune-modified RECIST (imRECIST) criteria, designed to...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of clinical oncology Jg. 36; H. 9; S. 850
Hauptverfasser:	Hodi, F Stephen, Ballinger, Marcus, Lyons, Benjamin, Soria, Jean-Charles, Nishino, Mizuki, Tabernero, Josep, Powles, Thomas, Smith, David, Hoos, Axel, McKenna, Chris, Beyer, Ulrich, Rhee, Ina, Fine, Gregg, Winslow, Nathan, Chen, Daniel S, Wolchok, Jedd D
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	United States 20.03.2018
Schlagworte:	Antibodies, Monoclonal - therapeutic use Antineoplastic Agents - therapeutic use Carcinoma, Non-Small-Cell Lung - immunology Carcinoma, Non-Small-Cell Lung - therapy Carcinoma, Renal Cell - immunology Carcinoma, Renal Cell - therapy Clinical Trials, Phase I as Topic Clinical Trials, Phase II as Topic Humans Immunotherapy - methods Kidney Neoplasms - immunology Kidney Neoplasms - therapy Lung Neoplasms - immunology Lung Neoplasms - therapy Melanoma - immunology Melanoma - therapy Neoplasms - immunology Neoplasms - therapy Progression-Free Survival Urologic Neoplasms - immunology Urologic Neoplasms - therapy
ISSN:	1527-7755, 1527-7755
Online-Zugang:	Weitere Angaben
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!